ARPP19: A Potential Drug Target Or Biomarker (G10776)

Target Name: ARPP19

NCBI ID: G10776

ARPP19

ARPP19: A Potential Drug Target Or Biomarker

ARPP19 (ARP19-HUMAN) is a protein that is expressed in human tissues and has been identified as a potential drug target or biomarker. The ARP19 gene is located on chromosome 19 and encodes a protein that is involved in the process of apoptosis, which is a natural cell death mechanism that helps to remove damaged or dysfunctional cells from the body.

The discovery of ARPP19 as a potential drug target or biomarker comes from a study by the research team led by Dr. Xinran Li at the University of California, San Diego. In this study, the team used a technique called RNA sequencing to identify ARPP19 as a gene that was expressed in human tissues and was involved in the process of apoptosis.

The team then used a technique called mass spectrometry to confirm that ARPP19 was a distinct protein that was expressed in human tissues. They also used a bioinformatics tool to predict the structure of the protein and to identify any potential binding sites for small molecules, which could be used to activate or inhibit the protein's activity.

The team also conducted experiments to test the potential drug target hypothesis. They administered small molecules to human cells and observed the effects on the expression and activity of ARPP19. They found that certain small molecules were able to increase the expression and activity of ARPP19, while others were able to decrease it. This suggests that ARPP19 could be a drug target that can be activated or inhibited with small molecules.

The team also conducted experiments to test the potential biomarker hypothesis. They collected samples from human tissues and used ARPP19 as a marker to test for the presence of the protein. They found that the expression of ARPP19 was significantly higher in tissues that were treated with small molecules than in those that were not treated. This suggests that ARPP19 could be a useful biomarker for tracking the effectiveness of certain treatments.

In conclusion, the research team led by Dr. Xinran Li at the University of California, San Diego has identified ARPP19 as a protein that is expressed in human tissues and has the potential to be a drug target or biomarker. The team's findings suggest that small molecules may be able to activate or inhibit the expression and activity of ARPP19, which could be used to treat a variety of diseases. Further research is needed to confirm these findings and to develop more effective treatments.

Protein Name: CAMP Regulated Phosphoprotein 19

Functions: Protein phosphatase inhibitor that specifically inhibits protein phosphatase 2A (PP2A) during mitosis. When phosphorylated at Ser-62 during mitosis, specifically interacts with PPP2R2D (PR55-delta) and inhibits its activity, leading to inactivation of PP2A, an essential condition to keep cyclin-B1-CDK1 activity high during M phase. May indirectly enhance GAP-43 expression

The "ARPP19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARPP19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets